Mariana Lemos Duarte

Dr. Mariana Lemos Duarte

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2024 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
MZMichael Z. Zhong
Michael Z. Zhong
TPThomas Peng
Thomas Peng
MDMariana Lemos Duarte
Mariana Lemos Duarte
MWMinghui Wang
Minghui Wang
DCDongming Cai
Dongming Cai
Alzheimer’s disease (AD) is the most common neurodegenerative disease in the United States (US). Animal models, specifically mouse models have been developed to better elucidate disease mechanisms and test therapeutic strategies for AD. A large portion of effort in the field was focused on developing transgenic (Tg) mouse models through over-expression of genetic mutations associated with familial AD (FAD) patients. Newer generations of mouse models through knock-in (KI)/knock-out (KO) or CRISPR gene editing technologies, have been developed for both familial and sporadic AD risk genes with the hope to more accurately model proteinopathies without over-expression of human AD genes in mouse brains. In this review, we summarized the phenotypes of a few commonly used as well as newly developed mouse models in translational research laboratories including the presence or absence of key pathological features of AD such as amyloid and tau pathology, synaptic and neuronal degeneration as well as cognitive and behavior deficits. In addition, advantages and limitations of these AD mouse models have been elaborated along with discussions of any sex-specific features. More importantly, the omics data from available AD mouse models have been analyzed to categorize molecular signatures of each model reminiscent of human AD brain changes, with the hope to guide future selection of most suitable models for specific research questions to be addressed in the AD field.

4 November 2014 in Science Signaling
Verified
Journal Article
Closed access
PDF file
MDMariana Lemos Duarte
Mariana Lemos Duarte
DPDarlene Aparecida Pena
Darlene Aparecida Pena
FFFelipe Augusto Nunes Ferraz
Felipe Augusto Nunes Ferraz
DBDenise Aparecida Berti
Denise Aparecida Berti
TSTiago José Paschoal Sobreira
Tiago José Paschoal Sobreira
DSDeborah Schechtman
Deborah Schechtman
Kinases can recognize consensus motifs that are noncontiguous in folded proteins.

16 April 2020 in Trends in Neurosciences
Verified
Journal Article
Closed access
MDMariana Lemos Duarte
Mariana Lemos Duarte
LDLakshmi Devi
Lakshmi Devi

22 August 2022 in Human Molecular Genetics
Verified
Journal Article
Closed access
PDF file
WEWang Erming
Wang Erming
MDMariana Lemos Duarte
Mariana Lemos Duarte
LRLauren E Rothman
Lauren E Rothman
DCDongming Cai
Dongming Cai
BZBin Zhang
Bin Zhang
Neurodegenerative diseases such as Alzheimer’s disease (AD) are characterized by the progressive loss of neurons in the brain and the spinal cord. The pathophysiology of AD is multifactorial with heterogeneous molecular manifestations. The lack of efficacious therapies for AD reinforces the importance of exploring in depth multifaceted disease mechanisms. Recent progresses on AD have generated a large amount of RNA-sequencing data at both bulk and single cell levels and revealed thousands of genes with expression changes in AD. However, the upstream regulators of such gene expression changes are largely unknown. Non-coding RNAs (ncRNAs) represent the majority of the human transcriptome, and regulatory ncRNAs have been found to play an important role in regulating gene expression. A single miRNA usually targets a number of mRNAs and thus such ncRNAs are particular important for understanding disease mechanisms and developing novel therapeutics. This review aims to summarize the recent findings on the roles of ncRNAs in AD from ncRNA-omics studies with a focus on ncRNA signatures, interactions between ncRNAs and mRNAs, and ncRNA-regulated pathways in AD. We also review the potential of specific ncRNAs to serve as biomarkers and therapeutic targets for AD. In the end, we point out future directions for studying ncRNAs in AD.

9 May 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
LCLuis Felipe Campesato
Luis Felipe Campesato
ASAna Paula M. Silva
Ana Paula M. Silva
LCLuna Cordeiro
Luna Cordeiro
BCBruna R. Correa
Bruna R. Correa
FNFabio C. P. Navarro
Fabio C. P. Navarro
ACAnamaria Camargo
Anamaria Camargo
High IL-1R8 expression in breast tumors promotes tumor growth and contributes to impaired antitumor immunity High IL-1R8 expression in breast tumors promotes tumor growth and contributes to impaired antitumor immunity

1 July 2022 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
SMSeshat M. Mack
Seshat M. Mack
IGIvone Gomes
Ivone Gomes
AFAmanda K. Fakira
Amanda K. Fakira
MDMariana Lemos Duarte
Mariana Lemos Duarte
AGAchla Gupta
Achla Gupta
LDLakshmi Devi
Lakshmi Devi
PEN is an abundant neuropeptide that activates G protein-coupled receptor 83 (GPR83), which is considered a novel therapeutic target due to its roles in regulation of feeding-, reward-, and anxiety-related behaviors. The major form of PEN in the brain is 22 residues in length. Previous studies have identified shorter forms of PEN in mouse brain and neuroendocrine cells; these shorter forms were named PEN18, PEN19, and PEN20, with the number reflecting the length of the peptide. The C-terminal five residues of PEN20 are identical to the C-terminus of a procholecystokinin (proCCK)-derived peptide, named proCCK56-62, that is present in mouse brain. ProCCK56-62 is highly conserved across species, although it has no homology to the bioactive cholecystokinin domain. ProCCK56-62 and a longer form, proCCK56-63, were tested for their ability to engage GPR83. Both peptides bind GPR83 with high affinity, activate second messenger pathways, and induce ligand-mediated receptor endocytosis. Interestingly, the shorter PEN peptides, ProCC56-62 and ProCCK56-63, differentially activate signal transduction pathways. Whereas PEN22 and PEN20 facilitate receptor coupling to Gαi, PEN18, PEN19, and ProCCK peptides facilitate coupling to Gαs. Furthermore, the ProCCK peptides exhibit dose-dependent Gα subtype selectivity in that they facilitate coupling to Gαs at low concentrations and Gαi at high concentrations. These data demonstrate that peptides derived from two distinct peptide precursors can differentially activate GPR83 and that GPR83 exhibits Gα subtype preference depending on the nature and concentration of the peptide. These results are consistent with the emerging idea that endogenous neuropeptides function as biased ligands. SIGNIFICANCE STATEMENT We found that peptides derived from procholecystokinin (proCCK) bind and activate G protein-coupled receptor 83, which is known to bind peptides derived from proSAAS. Different forms of the proCCK- and proSAAS-derived peptides show biased agonism, activating Gαs or Gαi depending on the length of the peptide and/or its concentration.